Home
Contact

Links

PsiOxus Therapeutics / Links

Comments are closed.

PsiOxus in the News

PsiOxus Upcoming Events

PsiOxus Awards & Achievements

Recent Posts

PsiOxus Therapeutics Announces First-in-Human Dosing of their Second Gene Therapy Cancer Treatment.
PsiOxus Therapeutics to Collaborate with the Parker Institute for Cancer Immunotherapy
PsiOxus Therapeutics Receives $15 Million Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves CTA
PsiOxus Therapeutics is listed in FierceBiotech’s 2017 Fierce 15
PsiOxus Therapeutics listed in 2017 Sunday Times Hiscox 100

Filter Publications

Enadenotucirev Preclinical
Enadenotucirev Clinical
T-SIGn
Reviews

Vision & Strategy

Vision & Strategy

We aim to be the world's leading cancer gene therapy company.

Technology & Products

T-SIGn Platform & Products

View our advanced pipeline of products.

Clinical Trials

Clinical Trials

View information on our clinical trials here.

People & Investors

People & Investors

PsiOxus brings together highly experienced management and investors.

Latest News & Events

PsiOxus Therapeutics Announces First-in-Human Dosing of their Second Gene Therapy Cancer Treatment.

13th March 2019

PsiOxus Therapeutics to Collaborate with the Parker Institute for Cancer Immunotherapy

15th November 2018

PsiOxus Therapeutics Receives $15 Million Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves CTA

12th December 2017

logo

Email
Links
Sitemap
Privacy Policy

Copyright

Designed and Produced by www.imageworks.co.uk
© Copyright 2019 PsiOxus Therapeutics

© Copyright 2020 PsiOxus Therapeutics

RSS

About
Pipeline
- Pipeline
- Enadenotucirev
- T-SIGn Platform
- NG-348
- NG-350A
- NG-641
- Publications
Clinical Trials
News & Events
- PsiOxus in the News
Contact

Responsive Menu Pro Image

Responsive Menu Clicked Image

Menu